The effects of the novel <scp>SHIP</scp>1 activator <scp>AQX</scp>‐1125 on allergen‐induced responses in mild‐to‐moderate asthma

Abstract

AQX-1125, a novel oral SHIP1 activator, significantly reduces the late response to allergen challenge, with a trend to reduce airway inflammation. AQX-1125 was safe and well tolerated and merits further investigation in inflammatory disorders.